An Open Label Randomized Controlled Phase II Trial of Panitumumab in Combination With Epirubicin, Cisplatin and Capecitabine (ECX) Versus ECX Alone in Subjects With Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction.
Phase of Trial: Phase II
Latest Information Update: 01 Mar 2018
At a glance
- Drugs Panitumumab (Primary) ; Capecitabine; Cisplatin; Epirubicin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms NEOPECX
- 01 Mar 2018 Results published in the European Journal of Cancer
- 19 Jan 2018 Status changed from active, no longer recruiting to completed.
- 08 Aug 2017 Planned End Date changed from 1 Jul 2017 to 1 Aug 2017.